A Narrative Review on the Management of Severe COVID-19 Infection Using Stem Cell-Based Therapies with a Focus on the Registered Clinical Trials
Preprint
- 26 March 2024
- preprint
- Published by Qeios Ltd
- Vol. 6 (3)
Abstract
The emergence of SARS-CoV-2 has led to a concerning global pandemic. The severity of COVID-19 symptoms may be enhanced due to underlying medical conditions. Several studies have demonstrated that severe COVID-19 infection can lead to innate and adaptive immune dysregulation, hypercytokinemia, as well as the formation of fibro myxoid exudate in the respiratory alveoli, ultimately resulting in pulmonary fibrosis and ARDS as the leading causes of mortality and morbidity. Currently, there is a widespread global endeavor to find efficient drugs or vaccines to manage COVID-19. Although some FDA-approved treatments have been introduced for COVID-19, alternative therapies might decrease mortality rates. Various sources of stem cell-derived exosomes, pluripotent stem cells, and mesenchymal stem cells as cell-based therapies have been applied to moderate to severe COVID-19 patients with ARDS, leading to positive results. Cell-based therapies can probably inhibit tissue remodeling and subsequent end-organ damage by modulating the cytokine cascades and cellular apoptosis. The present review aims to discuss the advantages of stem cell-based therapies in the treatment of COVID-19 patients and the possible challenges associated with their application.Keywords
All Related Versions
This publication has 112 references indexed in Scilit:
- Safety and efficacy of mesenchymal stem cells in COVID‐19 patients: A systematic review and meta‐analysisImmunity, Inflammation and Disease, 2023
- Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trialStem Cells Translational Medicine, 2021
- Stem cell therapy for COVID‐19: Possibilities and challengesCell Biology International, 2020
- The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expectStem Cells Translational Medicine, 2020
- The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic InfectionJAMA Neurology, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Coronavirus Disease 2019 and Influenza 2019-2020JAMA, 2020
- The role of microRNAs in embryonic stem cell and induced pluripotent stem cell differentiation in male germ cellsJournal of Cellular Physiology, 2018
- Application of induced pluripotent stem cell and embryonic stem cell technology to the study of male infertilityJournal of Cellular Physiology, 2018
- Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 CountriesJAMA, 2016